4 January 2016 - In recent weeks, the increasing prices of off-patent pharmaceuticals have been the subject of extensive news coverage and debate, a public meeting at the Department of Health and Human Services, and hearings in both houses of Congress.

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2480263&utm_source=Silverchair%20Information%20Systems&utm_medium=email&utm_campaign=JAMA%3AOnlineFirst01%2F04%2F2016